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Hepatitis C virus (HCV) contributes substantially to human morbidity and mortality world-wide.
The development of HCV genomes expressing heterologous proteins has enhanced the ability to study
viral infection, but existing systems have drawbacks. Recombinant viruses often require adaptive
mutations to compensate for reduced viral titers, or rely on an artiﬁcial genomic organization that
uncouples viral protein expression from recombinant gene expression. Here, we sought to exploit the
viral polyprotein processing machinery to express heterologous proteins within the context of the HCV
polyprotein. We show that HCV genotypes 2a and 1b permit insertion of reporter proteins between
NS5A and NS5B with minimal impact on viral ﬁtness. Using this strategy we constructed reporter
genomes exhibiting a wide dynamic range, simplifying analysis of HCV infection in primary hepatocytes.
Expression of heterologous proteins within the HCV genome offers new opportunities to analyze HCV
infection in experimental systems without perturbing functions of individual viral proteins.
& 2013 Elsevier Inc. All rights reserved.Introduction
Despite the advent of improved antiviral therapy HCV remains
a major medical problem with at least 130 million chronic
carriers world-wide. Progress in generating more effective ther-
apeutics has been delayed by the difﬁculty of studying HCV in cell
culture. HCV was identiﬁed as the etiologic agent causing non-A/
non-B hepatitis in 1989 (Choo et al., 1989) but it was not until a
decade later that it became possible to study HCV RNA replication
in cell culture using HCV replicons, HCV RNA genomes harboring
dominant selectable markers (Blight et al., 2000; Lohmann et al.,
1999). In 2005 it was demonstrated for the ﬁrst time that a
unique HCV isolate derived from a Japanese patient with fulmi-
nant hepatitis, termed JFH1, could complete the entire viral life-
cycle in vitro (Lindenbach et al., 2005; Wakita et al., 2005; Zhong
et al., 2005). Despite considerable effort, it has proven difﬁcult to
identify additional genomes, which, like JFH1, robustly replicate
in cell culture. Based on cDNA clones of the HCV Hutchinson
strain, which generated RNA transcripts shown to be infectious
in vivo (Kolykhalov et al., 1997), a genotype 1a infection system
(H77S) has been generated (Yi et al., 2006). The H77S genome
contains multiple cell culture-adaptive mutations distributedll rights reserved.throughout the nonstructural protein-coding region which permit
robust RNA replication in human hepatoma cells and moderate
titers of cell culture-infectious virus, although at signiﬁcantly
lower levels than JFH1 (Yi et al., 2006). The most commonly used
tissue culture systems supporting HCV infection rely heavily on
the human hepatoma cell line Huh7 and its derivatives (Blight
et al., 2002a; Friebe et al., 2005; Zhong et al., 2005), originally
derived from a 57 year-old Japanese male patient with a well-
differentiated liver cancer (Nakabayashi et al., 1982). A few other
cell lines support HCV RNA replication to some extent, including
LH86 cells (Zhu et al., 2007). Expression of the liver speciﬁc
microRNA (miR) 122 renders two human hepatoma cell lines,
Hep3B and HepG2 supplemented with CD81, and even a non-
hepatic 293T cells supplemented with CLDN1, mir122, and apoE
permissive to HCV infection (Da Costa et al., 2012; Kambara et al.,
2011; Narbus et al., 2011). Hepatoma lines have certainly been
instrumental for studies of the HCV lifecycle, but abnormal
proliferation and deregulated gene expression of continuously
growing cancer cell lines may not reﬂect the behavior of hepato-
cytes in vivo. Establishing systems for HCV replication and virus
production in primary culture has proven challenging (reviewed
in Sheahan et al. (2010)): primary human hepatocytes quickly
dedifferentiate in cell culture, infection is often hampered by a
low dynamic range and considerable donor-to-donor variation,
and primary liver tissue is scarce and costly.
The study of HCV has been greatly facilitated by the use of
reporter systems to monitor various phases of the viral life cycle.
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permissive cell culture systems (Jones et al., 2010) and by the
generation of recombinant HCV genomes expressing heterologous
proteins such as ﬂuorescent markers (Jones et al., 2010), luciferases
(Gottwein et al., 2011b), and Cre recombinase (Dorner et al., 2011).
Though recombinant genomes are more versatile with respect to the
choice of culture system and reporter model, a major caveat is that
recombinant HCV genomes are often less ﬁt than wild-type strains,
and may require signiﬁcant adaptation in order to reach sufﬁciently
high titers for experimentation (Gottwein et al., 2011b). It was
recently shown that heterologous proteins can be fused within
Domain III of NS5A, but only yield sufﬁcient titers when they acquire
in-frame adaptive deletions in NS5A Domain II through passaging
(Gottwein et al., 2011a). A different approach for overcoming ﬁtness
losses conferred by gene insertion employs a bicistronic model in
which the viral proteins are translated from an encephalomyocardi-
tis virus internal ribosomal entry site (EMCV-IRES), while the
reporter gene is driven from ribosomal binding to the HCV 50
untranslated region (50UTR) (Jones et al., 2007). Such bicistronic
viruses may not require adaptation, but viral proteins are translated
through unnatural non-HCV mechanisms. The artiﬁcial nature of
HCV genomes requiring either adaptation or the use of a second
cistron highlight the need for alternative strategies for generating
robust, non-adapted, monocistronic recombinant HCV genomes.
HCV contains a single-stranded plus-strand RNA genome in
which the 50 untranslated region (50UTR) serves as a ribosomal
entry site from which all viral proteins are translated in a single
continuous polyprotein in the order NH2-C-E1-E2-p7-NS2-NS3-
NS4A-NS4B-NS5A-NS5B-COOH (Bartenschlager and Lohmann,
2000). Polyprotein processing occurs by multiple mechanisms:
endogenous signal peptidases mediate cleavage of structural
proteins core, E1, E2 and the p7-NS2 junction including signal-
peptide peptidase cleavage of core from the E1 signal peptide
(Lindenbach and Rice, 2005), while processing of nonstructural
proteins occurs by a combination of autoproteolytic and trans-
cleavage processes. The present model (reviewed in Morikawa
et al. (2011)) suggests that dimerized NS2, together with the
N-terminal domain of NS3, mediates autoproteolytic cleavage of
NS2 cleavage from NS3. NS3 in cis cleaves NS4A from itself and
NS4B, followed by the association of NS4A with the N-terminus of
NS3 to form the NS3-4A protease complex (Kolykhalov et al.,
1994). NS3-4A is responsible for cleavage at the NS4B/NS5A and
NS5A/NS5B junctions in trans (Grakoui et al., 1993; Kolykhalov
et al., 1994). The NS3-4A protease is also known to cleave at least
two cellular targets, Toll-like receptor 3 adaptor protein (TRIF)
(Li et al., 2005a), mitochondrial antiviral signaling protein (MAVS)
(Li et al., 2005b; Meylan et al., 2005), to blunt the innate immune
response to viral infection and the action of T-cell protein tyrosine
phosphatase (TC-PTP) which results in EGF-induced signal trans-
duction (Brenndorfer et al., 2009). The speciﬁc molecular deter-
minants of both cellular and viral cleavage targets of the NS3-4A
protease have started to emerge (Bartenschlager et al., 1994;
Lin et al., 1994; Romano et al., 2011) (and reviewed in Morikawa
et al. (2011)). We sought to use these known sequences to exploit
normal HCV polyprotein processing machinery for expression of
heterologous proteins within the context of a monocistronic HCV
genome.
Here we report a method for the generation of recombinant
HCV genomes on a monocistronic background without the need
for viral adaptation through passaging. The NS3-4A protease
complex cleaves NS5A from NS5B through speciﬁc recognition
of the amino acid region spanning the seven C-terminal residues
of NS5A and the two N-terminal residues of NS5B (Romano et al.,
2011). We show that duplication of this cleavage motif at amino-
and carboxy-termini of two reporter proteins, yellow ﬂuorescent
protein (YPet) and non-secreted Gaussia luciferase (nsGLuc),inserted between NS5A and NS5B results in normal polyprotein
processing and yields high viral titers. We further demonstrate that
reporter expression in this model matches or exceeds that of
existing reporter genomes on both mono- and bicistronic back-
grounds, and show that reporter expression exhibits a wide dynamic
range that simpliﬁes longitudinal analysis of HCV infection in
primary hepatocytes. Finally, we show that this model is tolerated
by multiple genotypes, including the non-JFH1-based HCV Con1
(1b). Expression of heterologous proteins in the context of the HCV
polyprotein offers new opportunities to analyze HCV infection in
experimental systems without perturbing the functions of indivi-
dual viral proteins or disrupting normal translational regulation.Results
Recombinant HCV genome development
We hypothesized that duplication of the NS3-4A-dependent
proteolytic cleavage site between NS5A and NS5B would permit
insertion of genes of interest into the HCV genome without
diminishing viral ﬁtness. Due to restriction site limitations in
JFH1-based vectors, we constructed a Gateways-based destina-
tion vector, Jc1-5AB-DEST, from the parental Jc1 (Pietschmann
et al., 2006) to facilitate gene insertion at the NS5A/5B site.
The nine-amino acid sequence spanning P7-P20 of the NS3-4A-
dependent proteolytic cleavage site between NS5A and NS5B is
encoded at both ends of the destination cassette (Fig. 1a). All
excess amino acid residues associated with Gateways sites and
gene insertion are internal to the cleavage sequences, such that
NS5A and NS5B proteins should be identical to wild-type follow-
ing NS3-4A-mediated polyprotein processing. From Jc1-5AB-
DEST, we constructed recombinant HCV(2a) genomes of J6/JFH,
Jc1, and J6/JFH Clone2 containing the enhanced yellow ﬂuorescent
protein variant YPet (Nguyen and Daugherty, 2005). To assess
whether insertion of the 5AB YPet expression cassette affected
viral ﬁtness, we compared viral growth kinetics of Jc1 5AB YPet to
the parental Jc1 genome. As a control we also compared another
recombinant monocistronic Jc1 genome described elsewhere
(Oh and Jones et al., in preparation) in which YPet is fused to
NS5A Domain III and harbors an adaptive deletion of 34 amino
acids in NS5A Domain II (Jc1(D34-378-YPet)). While the number
of HCV NS5A-positive cells was similar for all three genomes one
day after electroporation, the Jc1 5AB YPet genome exhibited
fewer NS5A-positive cells on day two but reached levels similar to
Jc1 and Jc1(D34-378-YPet) by day 4 (Fig. 1b). This suggested that
insertion of YPet between NS5A and NS5B minimally impairs
replicative ﬁtness. Encouragingly, however, viral titers were very
similar for Jc1, Jc1(D34-378-YPet) and Jc1 5AB YPet, peaking
between 1105106 TCID50/ml (Fig. 1c). YPet expression was
readily detectable by ﬂow cytometry within 24 h post electro-
poration in Huh-7.5 cells harboring the Jc1 (D34-378-YPet) or Jc1
5AB YPet genomes (Fig. 1e). Expression of endogenous NS5A
(Fig. 1d) and YPet (Fig. 1e) were similar for both reporter
genomes. To determine whether NS5A and NS5B are properly
processed in the Jc1 5AB reporter genome we visualized both
proteins by western blot in cell lysates at 24 h, 48 h, and 72 h
following electroporation. NS5A and NS5B migrated with the
expected molecular mass of approximately 56 kDa and 65 kDa,
respectively (Fig. 1f). Bands indicative of incompletely processed
NS5A and/or NS5B bound to YPet were not detectable for either
Jc1 or Jc1 5AB Ypet. Expectedly, Jc1(D34-378-YPet) NS5A ran at
higher molecular weight due to its fusion to YPet. These data
show that YPet is efﬁciently cleaved from both ﬂanking HCV
proteins NS5A and NS5B in the Jc1 5AB YPet genome, indicating
that YPet insertion does not impair polyprotein processing or
Fig. 1. Gene insertion between NS5A and NS5B does not impair viral ﬁtness. (a) Genome structure of the Jc1(D34-378-YPet) and Jc1 5AB YPet illustrating the insertion of
YPet either as a fusion protein with NS5A with a subsequent adaptive deletion in domain II (DII) or by duplicating the NS3-4A protease cleavage site between NS5A and
NS5B (5A/B CS) ﬂanking the YPet insertion. (b) HCV replication following electroporation of in vitro transcribed RNA of Jc1, Jc1(D34-378-YPet) or Jc1 5AB YPet into Huh-7.5
cells as measured by ﬂow cytometry. (c) Longitudinal virus production as measured by end-point limiting dilution following electroporation of Jc1, Jc1(D34-378-YPet) or
Jc1 5AB YPet RNA into Huh-7.5 cells. Results shown are means7SD from three independent experiments (b, c). (d, e) Histograms of (d) NS5A and (e) YPet expression
following electroporation of Huh-7.5.1 cells with Jc1, Jc1(D34-378-YPet), or Jc1 5AB YPet. (f) NS5A/5B cleavage at different times post electroporation of Jc1, Jc1(D34-378-
YPet) or Jc1 5AB YPet into Huh-7.5 cells as measured by Western blot against either NS5A or NS5B.
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proteins.
Instability of HCV reporter genomes over serial passage
Next, we aimed to determine the stability of heterologous protein
expression in recombinant monocistronic genomes through serial
passage. Jc1 5AB genomes were generated expressing either oneor two YPet proteins, which increased the size of the insert from
700 bp to 1500 bp (230 aa to 500 aa). Both Jc1 5AB YPet and
Jc1 5AB 2xYPet genomes replicated equally efﬁciently (data not
shown) and produced similar viral titers reaching approximately
1106 TCID50/ml (Fig. 2a). Expression of two copies of YPet
increased the sensitivity of the reporter by ca. 5-fold over Jc1
5AB YPet or the Jc1(D34-378-YPet) – each harboring a single
copy of YPet per genome - in electroporated Huh-7.5 cells (Fig. 2b).
Fig. 2. Ypet insertion into the HCV genome is unstable through serial passage. (a) Longitudinal virus production in Huh-7.5 cells following electroporation of Jc1(D34-378-
YPet), Jc1 5AB YPet or Jc1 5AB 2xYPet in which two copies of YPet separated by a GS-linker are inserted between NS5A and NS5B. (b) Mean ﬂuorescence intensity of YPet
following electroporation of Jc1(D34-378-YPet), Jc1 5AB YPet or Jc1 5AB 2xYPet into Huh-7.5 cells. (c-e) Genomic stability of (c) Jc1(D34-378-YPet), (d) Jc1 5AB YPet and
(e) Jc1 5AB 2xYPet over multiple passages. Electroporated cells were passaged and cells were analyzed for the expression of NS5A and YPet by ﬂow cytometry at the
indicated time points. Results shown are means7SD of three independent experiments.
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heterologous proteins, we serially passaged Huh-7.5 cells electro-
porated with each of the three YPet-containing genomes. While the
frequency of NS5A positive cells remained stable over time for Jc1
(D34-378-YPet) (Fig. 2c) and Jc1 5AB YPet (Fig. 2d), and only slightly
decreased in cells infected with the Jc1 5AB 2xYPet genome (Fig. 2e),
the frequency of YPet positive cells decreased rapidly after the
second passage of Huh-7.5 cells harboring the Jc1 5AB 2xYPet
genome. YPet ﬂuorescence was almost completely lost by the third
passage of Huh-7.5 cells replicating Jc1 5AB 2xYPet (Fig. 2e),
compared with only a ca. 2-fold reduction in reporter expression
for both Jc1 (D34-378-YPet) (Fig. 2c) and Jc1 5AB YPet after six
passages (Fig. 2d). These data show that YPet insertion into the HCV
genome on a monocistronic background is unstable through serial
passage, and that duplication of the heterologous insert drastically
increases reporter expression at the cost of substantially greater
genomic instability. This ﬁnding highlights the potential utility
of reporter gene duplication for expanding dynamic range and
signal-to-noise ratios in single-round viral infection settings. Taken
together these data suggest that despite limited genomic stability
following serial passage, gene insertion at the NS5A/5B junction as
we describe permits robust heterologous protein expression during
short-term infection.
Insertion of reporter genes between HCV NS5A and NS5B maintains
the viral phenotype of parental genomes
Insertion of heterologous proteins into monocistronic HCV
genomes often decreases viral ﬁtness by affecting replicationefﬁciency, production of infectious particles and the ability to
spread. Our data demonstrate that the viral ﬁtness of the Jc1
genome is only marginally affected by insertion of YPet between
NS5A and NS5B. To test whether this strategy would allow us to
preserve distinct features of HCV genomes, we inserted the 5AB
YPet cassette into the parental J6/JFH1 (Lindenbach et al., 2005)
and its cell culture-adapted derivative, termed J6/JFH1 clone 2,
which was shown to produce higher viral titers and is believed to
spread more efﬁciently than J6/JFH1 or Jc1 in cell culture (Andrus
et al., 2011; Walters et al., 2009). The J6/JFH1 and J6/JFH1 clone
2 genomes replicate equally efﬁciently following electroporation
into Huh-7.5 cells irrespective of heterologous reporter gene
insertion between NS5A and NS5B (Fig. 3a and c). As previously
reported (Andrus et al., 2011; Walters et al., 2009) J6/JFH1 clone
2 produces approximately 10-fold higher titers than the parental
J6/JFH1 genome (Fig. 3b). Importantly, the insertion of YPet
between NS5A and NS5B in either J6/JFH1 or J6/JFH1 clone
2 resulted in infectivity titers similar to parental genomes,
peaking around 1105 and 1106, respectively (Fig. 3d). J6/
JFH1 clone 2 5AB YPet preserved the increased ﬁtness of the clone
2 variant over J6/JFH1 5AB YPet, suggesting that the insertion of
reporter genes between NS5A and NS5B does not affect the viral
phenotype of parental genomes.
To further explore the utility of this genome conﬁguration we
compared genomes expressing Gaussia luciferase (Gluc) between
either p7 and NS2 (Jc1(p7nsGluc2A) (Marukian et al., 2008),
J6/JFH1 (p7nsGluc2A), J6/JFH1 clone 2(p7nsGluc2A)) or between
NS5A and NS5B (Jc1 5AB nsGluc, J6/JFH1 clone 2 5AB nsGluc)
(Fig. 4a). Following electroporation of RNA into Huh-7.5 cells the
Fig. 3. Gene insertion between NS5A/5B does not alter the viral phenotypes of distinct HCV genomes. (a, c) Replication, as measured by ﬂow cytometry of NS5A and (b, d)
longitudinal virus production of J6/JFH1, J6/JFH1 clone 2, J6/JFH1 5AB YPet and J6/JFH1 clone 2 5AB YPet. Results shown are means7SD of three independent experiments.
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the three p7nsGluc2A genomes (Fig. 4f) and all had similar
infectivity titers peaking around 1105–1106 TCID50/ml
(Fig. 4h). The percentage of NS5A positive cells was also similar
for Huh-7.5 cells electroporated with Jc1 5AB nsGluc or J6/JFH1
clone 2 5AB nsGluc RNA (Fig. 4g) but reached higher peak titers
than the p7nsGluc2A genomes, ranging from 1106–
1107 TCID50/ml (Fig. 4i). Very robust Gluc activity was detect-
able in both the supernatants (Fig. 4b) and lysates (Fig. 4d) of cells
electroporated with all of the p7nsGluc2A genomes and increased
over time proportionally to the number of NS5A positive cells
(Fig. 4f). In cells replicating the 5AB nsGluc genomes reporter
activity was only detectable in the cell lysates (Fig. 4e) but not in
the supernatants (Fig. 4c). These results were largely upheld
following infection of Huh-7.5 cells with a multiplicity of infec-
tion (MOI) of 0.1 of each of the respective genomes (Fig. 4j–o).
Interestingly, however, the frequency of NS5A positive cells was
lower at days 1 to 3 for J6/JFH1 clone 2(p7nsGluc2A) relative to
both J6/JFH1 clone 2 and J6/JFH1 clone 2 5AB nsGluc (Fig. 4o)
indicating that the p7nsGluc2A insertion leads to a loss of the
clone 2-associated viral phenotype. This suggests that insertion of
heterologous proteins between NS5A and NS5B may be more
suitable than insertions at other positions of the genome for
maintaining the speciﬁc viral characteristics of a given HCV
genome.
Characterization of luminescent 5AB reporter genomes in human
primary hepatocyte cultures
To further analyze the utility of the Gaussia luciferase 5AB
reporter insertion we monitored infection in primary hepatocytecultures. We have previously demonstrated that a monocistronic
secreted Gluc reporter inserted between p7 and NS2 (Jc1p(7ns-
Gluc2A)) (Marukian et al., 2011) enables sensitive detection of
HCV RNA replication in both micropatterned primary hepatocyte
cocultures (Jones et al., 2010; Ploss et al., 2010) and human
fetal liver cultures (Andrus et al., 2011; Marukian et al., 2011)
despite the low infection frequency of 1–3% with the Jc1 genome
(Jones et al., 2010; Ploss et al., 2010). J6/JFH1 clone 2 is capable
of spreading more robustly than Jc1 in primary hepatocytes
as visualized in real time (Andrus et al., 2011) by monitoring
of infection using a cell-based ﬂuorescent reporter system that
allows sensitive detection of individual HCV-infected cells (Jones
et al., 2010).
Based on our previous data, we hypothesized that the differ-
ence in the ability to spread in primary hepatocyte cultures
between Jc1 and J6/JFH1 clone 2 should be reﬂected by a greater
dynamic range of a luminescent reporter when inserted between
NS5A and NS5B (Fig. 5a). HCV infections in primary hepatocytes
even with highly sensitive reporter genomes are usually char-
acterized by a low signal to noise ratio in part due exacerbated
antiviral signaling, which limits the number of infected cells in a
culture and presumably keeps the level of replication per cell at a
low level (Andrus et al., 2011; Marukian et al., 2011). In contrast
to the minimal differences observed between the Jc1 and J6/JFH1
clone 2 genomes harboring the 5AB nsGluc insertions in highly
permissive Huh-7.5 cells (Fig. 4n and o), J6/JFH1 clone 2 5AB
nsGluc infected 3-4 fold more cells than Jc1 5AB nsGluc in human
fetal liver cells transduced with the TagRFPnlsMAVS reporter
(Jones et al., 2010) as measured by nuclear translocation of the
TagRFP signal (Fig. 5a and c). This higher infection frequency
resulted in a ca. 10-fold difference in luciferase signal between
Fig. 4. Insertion of Gaussia luciferase between NS5A/5B retains characteristics of parental genomes. (a) Schematic representations of reporter genomes harboring Gaussia
luciferase (Gluc) either followed by a FMDV 2A site inserted between p7 and NS2 (p7nsGluc2A) or Gluc between NS5A/5B (5AB nsGluc). (b–e, j–m) Gaussia luciferase
expression in (b, c, j, k) supernatants or (d, e, l, m) cell lysates, (f, g, n, o) NS5A-expression and (h, i) titers of the indicated genomes following (b–i) electroporation of
Huh-7.5.1 cells with in vitro transcribed RNA or (j–o) infection of Huh-7.5 cells with MOI¼0.1. Data shown are mean7SD of three to four independent experiments.
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Fig. 5. Viral characteristics of HCV with Gaussia luciferase inserted between NS5A and NS5B are maintained during infection of primary human hepatocytes. (a) Infection
frequency of primary human fetal hepatocytes with Jc1 5AB nsGluc or J6/JFH1 Clone 2 5AB nsGluc as determined by nuclear translocation in cells expressing
tagRFPnlsMAVS. (b) Gaussia luciferase expression in cell lysates following infection of hepatocytes with Jc1 5AB nsGluc or J6/JFH1 Clone 2 5AB nsGluc with or without the
NS5B inhibitor 20CMA. (c) Representative images of infected hepatocytes indicated by nuclear translocation of the tagRFPnlsMAVS reporter. Data shown are mean7SD of
four independent experiments.
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observed for J6/JFH1 clone 2 5AB nsGluc, compared with 5:1 for
Jc1 5AB nsGluc, both measured against infected cultures treated
with the NS5B polymerase inhibitor 20 C-methyl adenosine
(20CMA) (Fig. 5b).Characterization of an HCV genotype 1b NS5A/5B Gaussia luciferase
reporter genome
To explore whether gene insertion between NS5A/5B is toler-
ated by multiple HCV genotypes, we generated a recombinant
full-length HCV Con1(1b) genome expressing Gluc between
duplicate Con1(1b) NS5A/5B cleavage sites (termed Con1 5AB
nsGluc) as was done for Jc1 5AB nsGluc. Jc1 and Con1 Gluc
genomes were electroporated into Huh7.5 cells and cultured with
or without 20CMA. Luciferase expression for Con1 5AB nsGluc was
signiﬁcantly elevated over the 20CMA treated cultures (ca. 20-
fold) at 2-3 days post-electroporation, indicating that the recom-
binant genome was able to replicate successfully. However,the
Con1 genome replicated only transiently as Gluc activity returned
to background levels at day 5 post electroporation, in contrast to
the Jc1 5AB nsGluc genome which robustly replicated throughout
the duration of the experiment (Fig. 6b). Given the extremely low
levels of Con1 HCV RNA replication, we were not able to detect
HCV NS5A antigen by ﬂow-cytometry (Fig. 6a) or nuclear trans-
location of the TagRFPnlsMAVS reporter (Fig. 6c), both of which
readily allow quantitation of HCV replication in Jc1 5AB nsGluc
electroporated cells. These data demonstrate that the insertion of
nsGluc in a monocistronic conﬁguration provides a uniquely
sensitive readout to monitor HCV RNA replication even in non-
JFH1 derived genomes.In summary, these data demonstrate that viral ﬁtness is not
dramatically impaired by the insertion of YPet or nsGluc between
NS5A and NS5B. Importantly, expression of these heterologous
proteins within the context of the viral polyprotein did not alter
the distinct virological features of J6/JFH1 and its derivates Jc1
and J6/JFH1 clone 2, which could facilitate analysis of viral
determinants that contribute to HCV’s ability to spread and
establish persistent infection in physiological primary cell culture
systems. Additionally, gene insertion between NS5A/5B was
tolerated for both JFH-1 based HCV(2a) and full-length HCV
Con1(1b) genomes, suggesting that this strategy is not genotype-
restricted.Discussion
The present study demonstrates that native viral polyprotein
processing machinery can be successfully harnessed for the
purpose of generating robust recombinant HCV genomes. We
have shown that monocistronic HCV(2a) genomes on the JFH1
background are permissive for gene insertion between NS5A and
NS5B by duplication of the NS3-4A-dependent proteolytic clea-
vage site. Incorporation of heterologous proteins into the HCV
polyprotein in this way gives rise to expression levels that are
stoichiometrically linked to polyprotein expression. Viral protein
processing was shown to occur normally in this setting, with all
fusion products resulting from heterologous protein insertion
being efﬁciently cleaved from both NS5A and NS5B by action of
the NS3-4A protease.
This strategy for introducing heterologous proteins into the
HCV genome may be applicable for a variety of insert types
beyond the reporter molecules we have used in this study. If, as
Fig. 6. Sensitive detection of HCV RNA replication for a monocistronic HCV genotype 1b genome containing a Gaussia luciferase gene between NS5A and NS5B. (a, b) HCV
replication following electroporation of in vitro transcribed RNA of Jc1 5AB nsGluc or Con1 5AB ns Gluc into Huh-7.5 cells in the presence or absence of the NS5B
polymerase inhibitor 20CMA as measured by luciferase activity in cell lysates (a) or NS5A staining and ﬂow cytometry (b). (c, d, e, f) Representative images of Huh7.5 clone
8 cells electroporated with Jc1 5AB nsGluc (c, e) or Con1 5AB ns Gluc (d, f) indicated by nuclear translocation of the tagRFPnlsMAVS reporter at 100 (c, d) or 400 (d, f) fold
magniﬁcation. Data shown are mean7SD of three independent experiments.
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resulting from gene insertion are readily cleaved during poly-
protein processing, insertion at the NS5A/5B locus would have
signiﬁcant advantages over other gene insertion methods (e.g.
fusion to NS5A): inserts would be free to interact with other
cellular or viral elements outside of a fusion protein context, and
would be more likely to retain normal folding and function
because of the lack of steric interference from fusion counter-
parts. It may also be possible to introduce dominant selectable
markers, such as neo or blasticidin S-deaminase, into the HCV
genome at the NS5A/5B locus for in vitro selection of HCV-
replicating cell populations as with the replicon system. As
selectable marker expression in this context would be coupled
to viral polyprotein translation, such an approach could have
added utility over bicistronic full-length or subgenomic selectable
genomes in priming cell populations to replicate monocistronic
HCVs.
Admittedly, some gene insertions may be poorly tolerated at
the NS5A/5B locus. Protein inserts which occlude the NS5A/5B
cleavage domain immediately upstream of NS5B may prevent
proper cleavage and thereby impair polymerase activity, as could
occur in the case of large proteins with sequestered C-termini or
for inserts which multimerize in such a way that cleavage sitesare sterically blocked. Additionally, any insert that leads to
signiﬁcant decompartmentalization of NS5B during initial trans-
lation, such as one that includes cellular targeting signals, may
prevent sufﬁcient interaction with viral RNAs to achieve stable
replication.
The ﬁnding that heterologous protein expression is steadily
lost through passage despite normal viral replication and virus
particle production highlights the fragility of artiﬁcially manipu-
lated HCV genomes. The extremely high error rate of HCV
replication is likely to give rise to genomic transcripts lacking
functional reporter genes, which could rapidly come to predomi-
nate. This might occur if the reporter gene confers some minor
(perhaps undetectable) ﬁtness cost, and reporter-dysfunctional
mutants are selected, or because the reporter is non-essential to
the viral life cycle and becomes progressively diluted by tran-
scripts harboring loss-of-function mutations or deletions. The
latter hypothesis may well explain the gradual loss of reporter
strength (2-fold reduction after 6 passages) without visible ﬁtness
defects seen for both Jc1-5AB-Ypet and Jc1 (D34-378-YPet). In the
case of Jc1-5AB-2xYpet, reporter expression is lost so quickly that
the dilution hypothesis is unlikely, while multiple factors may
contribute to a ﬁtness cost. First, the sheer size of the 2xYpet
insertion may reduce the efﬁciency of viral genome packaging
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kicked out the insert; and second, the insertion of a dimerizing
fusion protein such as 2xYpet may disrupt local polyprotein
folding at the NS5A/NS5B locus and thereby reduce the efﬁciency
of proteolytic cleavage. The ﬁtness cost hypothesis is further
supported by the fact that the 2xYpet genome achieves a 10 fold
lower TCID50 at 96 days relative to parental and single-Ypet
genomes, and results in progressive loss of NS5A-positive cells
through passage.
Although we have explored only a limited number of inserts
within genotypes 2a and 1b, we have shown that recombinant
genome ﬁtness matches parental genome ﬁtness, and that this
holds across genomes with varying ﬁtness phenotypes. Other
JFH1-based genomes, such as the intergenotypic chimaeras
(Gottwein et al., 2009; Scheel et al., 2008), may behave similarly
to the genotype 2a intragenotypic variants tested here, and it is
likely that non-JFH1-based genomes from other genotypes would
be permissive for NS5A/5B gene insertion as we showed for Con1
5AB nsGluc. The successful generation of this genotype 1 reporter
genome may assist in the study of Con1(1b) and other non-2a
genotypes, which have been notoriously difﬁcult to manipulate in
tissue culture with few exceptions (Yi et al., 2006). The strategy
presented here may also be applicable to viruses other than HCV,
such as other Flaviviridae with genomic organizations similar to
that of HCV. The exploitation of viral processing mechanisms as
we have shown here for HCV may prove more inocuous than
existing methods for generating recombinant genomes on some
virus backgrounds. In sum, the present work outlines a versatile
new tool for expression of heterologous proteins in the context of
monocistronic HCV genomes, one that is likely to be applicable
beyond the limited examples provided in this study.Materials & methods
Culture of cell lines
Huh-7.5 (Blight et al., 2002b) Huh7.5 Clone 8 (Jones et al.,
2010) and Huh-7.5.1 (Zhong et al., 2005) were maintained in
Dulbecco’s Modiﬁed Eagle Medium (DMEM) (Invitrogen, Life
Technologies, Carlsbad, CA) supplemented with 5% heat inacti-
vated fetal bovine serum (FBS, Hyclone, Thermo Scientiﬁc, Waltham,
MA), 0.1 mM nonessential amino acids (Invitrogen, Life Technologies,
Carlsbad, CA).
Human subjects
All protocols involving human tissue were reviewed and
exempted by the Rockefeller University Institutional Review Board.
Isolation and culture of human fetal liver cells (HFLCs)
Human fetal liver cells were prepared as described previously
(Andrus et al., 2011). Brieﬂy, de-identiﬁed fetal livers (16–24
weeks gestation) were procured through Advanced Bioscience
Resources (ABR; Alameda, CA) or the Human Fetal Tissue Repo-
sitory of the Albert Einstein College of Medicine (AECOM; Bronx,
NY). Livers received on ice were washed with hepatocyte wash
buffer (HWB) consisting of Williams’ E Medium (WEM) plus
10 mM HEPES, 50 mg/ml gentamicin, 100 U/ml penicillin, and
100 mg/ml streptomycin (Invitrogen, Life Technologies, Carlsbad,
CA). Tissue was minced then resuspended in 20–40 ml warm
digestion buffer consisting of Hanks Balanced Salt Solution plus
40 mM HEPES, 3.26 mM CaCl2, 2 U/ml DNase I Grade II (Roche),
and 0.2% Collagenase type IV (Sigma). Tissue was digested for
30 min at 37 1C, then diluted 1:1 with HWB and gently pushedthrough 70 mm cell-strainers (BD Biosciences, San Diego, CA). The
suspension was centrifuged at 100 g for 3 min and the cell pellet
containing large hepatocytes was washed twice by resuspension
in 50 ml HWB and centrifugation at 100  g for 4 min. Hepato-
cytes were enriched by 1 g sedimentation in 25 ml HWB for 1 h
at room temperature, followed by additional washing. In some
experiments hepatocytes were further enriched by centrifugation
through lymphocyte separation medium (Cellgro, Manassas, VA)
as described (Schmelzer et al., 2007). Hepatocyte yields ranged
from 0.5 to 4107 cells per tissue and cells were generally 480%
viable as assessed by Trypan blue exclusion and collagen attach-
ment. Hepatocytes were plated at E1105/cm2 on 96-well
collagen I-coated plates (BD Biosciences, San Diego, CA) in WEM
containing 10% fetal bovine serum (FBS) (Omega Scientiﬁc,
Tarzana, CA), 2 mM L-glutamine (Invitrogen, Life Technologies,
Carlsbad, CA), 1 ITS Plus (BD Biosciences, San Diego, CA) and
antibiotics. After overnight incubation, adherent cells were
washed with WEM, then maintained in Hepatocyte Deﬁned
Medium (HDM; BD Biosciences, San Diego, CA) plus L-glutamine
and antibiotics. The culture medium was aspirated and replaced
every 2 days.
Transduction of HFLC with TagRFPnlsMAVS HCV infection reporter
Construction of the TRIP lentiviral vector expressing the
TagRFPnlsMAVS HCV reporter was described previously (Jones
et al., 2010). Pseudoparticles (PPs) were generated by co-trans-
fection of 293 T cells with TRIP-TagRFPnlsMAVS, HIV gag-pol, and
vesicular stomatitis virus envelope protein G (VSV-G) plasmids
using a ratio of 1:0.8:0.2, as described previously (Ploss et al.,
2009). HFLCs were transduced 1–3 days post-plating by incuba-
tion for 3–6 h with PP stocks diluted 1:3 in HDM supplemented
with 20 mM HEPES and 4 mg/ml polybrene, then washed and fed
with HDM.
Generation of recombinant HCV plasmids
J6/JFH1, Jc1 and Jc1FLAG2(p7-nsGluc2A) are fully-infectious
HCVcc viruses that have been previously described (Lindenbach
et al., 2005; Marukian et al., 2008; Pietschmann et al., 2006).
J6/JFH Clone2 is a passaged derivative of J6/JFH that contains a
number of adaptive mutations that increase infectious titers
(Walters et al., 2009). Con1/FL is a full-length HCV genotype 1b
virus described previously (Lohmann et al., 1999).
J6/JFH1 clone2 p7nsGluc2A: To construct the reporter virus
genome J6/JFH1 clone2 (p7nsGluc2A), we used the secreted
Gaussia luciferase (Gluc) cassette from the Jc1FLAG(p7-nsGluc2A)
genome (Marukian et al., 2008), in which the Gluc reporter, in
tandem with the foot and mouth disease autoproteolytic peptide
sequence (2A) is inserted between p7 and NS2. Brieﬂy, a unique
silent restriction site was introduced between the p7 and NS2
coding sequence at position 2784 (MluI) in J6/JFH1 clone 2 using
overlapping PCR mutagenesis. This site was used to insert the
573 bp DNA cassette encoding the p7nsGluc2A cassette excised
from Jc1FLAG(p7-nsGluc2A) into J6/JFH1 clone 2 by digestion
of both vectors with MluI enzyme. Bacterial plasmid clones
were screened for the correct orientation of the Gaussia luciferase
cassette.
Jc1(D34-378-YPet): A detailed description of the is prepared
elsewhere (Oh and Jones et al. manuscript in preparation).
HCVcc containing heterologous proteins between NS5A and NS5B:
We generated Gateways-compatible destination vectors (Invitro-
gen, Life Technologies, Carlsbad, CA) based upon the Jc1 and
Con1/FL HCV genomes, Jc1-5AB-DEST and Con1-5AB-DEST, for
insertion of reporter genes between NS5A and NS5B. The 9-amino
acid region spanning P7-P20 of the NS3-4A proteolytic cleavage
J.A. Horwitz et al. / Virology 439 (2013) 23–3332site between NS5A and NS5B was positioned on both ends of the
destination cassette. Jc1-5AB-DEST was generated by PCR ampli-
ﬁcation of the Gateways destination cassette, DEST (Invitrogen,
Life Technologies, Carlsbad, CA), and insertion into the DraIII
restriction site at the 30 end of Jc1(2a) NS5A using standard
molecular cloning techniques. Con1-5AB-DEST was similarly
generated by ampliﬁcation of DEST, PCR ligation to the ﬂanking
NS5A/NS5B regions of Con1/FL, and inserted into Con1/FL using
available restriction sites and standard molecular cloning techni-
ques. Jc1-5AB-YPet, Jc1-5AB-nsGLuc, Jc1-5AB-2xYPet and Con1-
5AB-nsGluc vectors were generated by PCR ampliﬁcation of YPet,
nsGLuc or two YPet molecules separated by a glycine-serine
linker, with primers containing AttB sites for Gateways-mediated
insertion into pDONRTM221, and subsequent BP and LR gateway
reactions were performed using the appropriate destination
vector. J6/JFH-5AB-YPet, J6/JFH Clone2-5AB-YPet, and J6/JFH
Clone2-5AB-nsGLuc vectors were generated from Jc1-5AB-YPet
and Jc1-5AB-nsGLuc using compatible restriction sites.
RNA transcription
In vitro transcripts were generated as previously described
(Lindenbach et al., 2005). Brieﬂy, plasmid DNA was linearized by
XbaI and puriﬁed by using a Minelute column (Qiagen, Valencia,
CA). RNA was transcribed from 1 mg of puriﬁed template by using
the T7 Megascript kit (Ambion, Austin, TX) or the T7 RNA
polymerase kit (Promega, Madison, WI). Reaction mixtures were
incubated at 37 1C for 3 h, followed by a 15-min digestion with
3 U of DNase I (Ambion, Austin, TX). RNA was puriﬁed by using an
RNeasy kit (Qiagen) with an additional on-column DNase treat-
ment. RNA was quantiﬁed by absorbance at 260 nm and diluted
to 0.5 mg/ml. Prior to storage at 80 1C, RNA integrity was
determined by agarose gel electrophoresis and visualization by
ethidium bromide staining.
RNA electroporation
Huh-7.5 cells were electroporated with RNA as previously
described (Lindenbach et al., 2005). Brieﬂy, Huh-7.5.1 cells were
treated with trypsin, washed twice with ice-cold RNase-free
AccuGene phosphate-buffered saline (PBS) (Bio-Whittaker, Rock-
land, ME), and resuspended at 1.75107 cells/ml in PBS. Then, 5 mg
of each RNA was combined with 0.4 ml of cell suspension and
immediately pulsed using a BTX ElectroSquare Porator ECM 830
(820 V, 99 ms, ﬁve pulses). Electroporated cells were incubated at
room temperature for 10 min prior to resuspension in 15 ml or
30 ml complete medium for nonreporter and reporter constructs,
respectively. Resuspended cells were plated into 24-well, 6-well,
and P100 tissue culture dishes.
HCV infection assays
Infectious units (as median tissue culture infective dose
[TCID50]) were quantiﬁed by limiting dilution titration on naı¨ve
Huh-7.5 cells (Lindenbach et al., 2005). For infection experiments
in primary human fetal hepatocytes, cells were seeded in 96 well
plates. On the third or fourth day after plating, human fetal
hepatocytes (1105/cm2) were infected with 3106 TCID50
units/well of HCVcc. Inocula were left in place for 6 h and then
removed with three washes (200 mL) of Williams E media without
serum and then maintained in hormonally deﬁned medium
containing indicated amounts of DMSO or 20CMA. Replication of
Gaussia luciferase expressing HCV genomes was monitored by
measurement of secreted Gluc in the supernatants or Gluc in
cell lysates.Flowcytometric analysis
For ﬂowcytometric analysis, cells were harvested using Accu-
Max (eBioscience) and ﬁxed using Fixation/Permeabilization
buffer (BD Biosciences, San Diego, CA) for 10 min at 4 1C. Fixed
cells were washed with BD Perm/Wash buffer (BD Biosciences,
San Diego, CA), incubated 30 min at RT with AlexaFluor-647-
conjugated 9E10 antibody (1:4000 in BD Perm/Wash buffer),
washed twice with BD Perm/Wash buffer and once with FACS
buffer (PBS/3%FBS) prior to analysis using a BD LSR II ﬂow
cytometer and BD FACSDiva software. Analysis of was performed
using FlowJo software.
Western blotting
Cells were lysed at the indicated times using modiﬁed RIPA
buffer containing 50 mM Tris-HCl pH 7.4, 1% v/v NP-40, 0.25% v/w
Na-deoxycholate, 150 mM NaCl, 1 mM EDTA, 1 mM PMSF, 1 mM
Sodium orthovanadate and 1 mM NaF for 20 min on ice. 15 mg of
protein lysate was separated on 4–12% Bis/Tris NuPage polyacry-
lamide gels (Invitrogen). Proteins were transferred to nitrocellu-
lose membranes and entry factors were detected using antibodies
against NS5A (9E10; 1:5000) (Lindenbach et al., 2005), NS5B
(4B8; 1:100)(Biofront Technologies) or beta-actin (AC15, 1:10000)
(Sigma). Following secondary antibody staining with Peroxidase-
AfﬁniPure Donkey Anti-Mouse IgG (HþL) (JIR, 1:10000) (Jackson
Immuno Research). Western blots were visualized using Super-
Signal West Pico (Thermo Scientiﬁc).
Fluorescence microscopy
Images were captured on an Axioplan 2 imaging ﬂuorescence
microscope (Zeiss, Thornwood, NY) using Metavue Software
(Molecular Devices, Sunnyvale, CA). Images were processed using
ImageJ software (NIH, Bethesda, MD).Acknowledgments
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